EUCTR2015-003148-38-FI进行中（未招募）1 期
A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 490
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent consistent with ICH-GCP and local laws, signed prior to participation in the trial including any study related procedures being performed;
- •- Male or female patients aged =40 years at Visit 1;
- •- A clinical diagnosis of IPF within the last 3 years from visit 0, based upon the ATS/ERS/JRS/ALAT 2011 guideline;
- •- Chest high resolution computed tomography (HRCT) scan performed within 18 months of Visit 0;
- •- Combination of HRCT pattern, and surgical lung biopsy pattern (the latter if available) as assessed by central review are consistent with the diagnosis of IPF;
- •- FVC =80% of predicted normal at Visit 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 330
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •- ALT, AST > 1.5 fold upper limit of normal (ULN) at visit 1;
- •- Total bilirubin > 1.5 fold ULN at visit 1;
- •- Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment);
- •- Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7 at visit 1);
- •- History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1;
- •- Bleeding Risk:
- •-- Known genetic predisposition to bleeding;
- •-- Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin etc.) or high dose antiplatelet therapy;
- •-- History of haemorrhagic central nervous system (CNS) event within 12 months prior to visit 1;
- •-- History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1;
- •-- International normalised ratio (INR) > 2 at visit 1;
- •-- Prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of ULN at visit 1;
- •- Planned major surgery during the trial participation, including lung transplantation, major abdominal or major intestinal surgery;
- •- History of thrombotic event (including stroke and transient ischemic attack) within 12 months of visit 1;
- •- Creatinine clearance < 30 mL/min calculated by Cockcroft-Gault formula at Visit 1;
- •- Treatment with nintedanib, pirfenidone, azathioprine, cyclophosphamide, cyclosporine, any other investigational drug, n-acetylcysteine, prednisone/prednisolone >15 mg daily or >30 mg every 2 days OR use of other systemic corticosteroids as well as other investigational drugs within 4 weeks of visit 2;
- •- Known hypersensitivity to nintedanib, peanut, soya or to any other components of the study medication;
- •- Prior discontinuation of nintedanib treatment due to intolerability/ adverse events considered drug related;
- •- A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial;
- •- Alcohol or drug abuse which in the opinion of the treating physician would interfere with the treatment and would affect patient's ability to participate in this trial;
- •- Patients not able to understand and follow study procedures such as but not limited to home spirometry, including completion of self-administered questionnaires without help;
- •- Women who are pregnant, nursing, who plan to become pregnant while in the trial or female patients with positive ß-HCG test at visit 1 and/or visit 2;
- •- Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly;
- •- Patients with acute IPF exacerbation or any respiratory tract infection in the four weeks prior to Visit 1 or during the screening period.
- •Visit 1 and/or Visit 2 should be postponed in case of an IPF exacerbation or respiratory tract infection. Refer to Section 6.1 for information on re-scheduling of visits;
- •- Patients who are currently participating in another trial or who have been participating in another trial within one month prior to Visit 1, and patients who have previously been enrolled in this trial.
研究者
相似试验
进行中（未招募）
1 期
Effect of nintedanib on biomarkersMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003148-38-PLBoehringer Ingelheim RCV GmbH & Co KG490
进行中（未招募）
1 期
Effect of nintedanib on biomarkersMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003148-38-BESCS Boehringer Ingelheim Comm. V490
进行中（未招募）
1 期
Effect of nintedanib on biomarkersMedDRA version: 19.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003148-38-GBBoehringer Ingelheim Limited471
进行中（未招募）
1 期
Effect of nintedanib on biomarkersMedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003148-38-FRBoehringer Ingelheim France471
进行中（未招募）
1 期
Effect of nintedanib on biomarkersMedDRA version: 18.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003148-38-CZBoehringer Ingelheim RCV GmbH & Co KG490